Published Abstracts

 

Modulation of glutaminolysis exposes novel genomic mediators of liver cancer progression.

Z.C. Nwosu, C. Meyer, S. Dooley.
European Journal of Clinical Investigation (2016), 46 (Suppl. 1), 6-119, 3.41.

TGF-β in progression of liver disease.

C. Meyer, S. Dooley.
European Journal of Clinical Investigation (2016), 46 (Suppl. 1), 6-119, 3.38. 

Smad7 deletion accelerates hepatocarcinogenesis and activates Stat3 signaling in diethylnitrosamine treated mice.

T. Feng, J. Dzieran, T. Maass, A. Teufel, S. Marhenke, A. Vogel, S. Dooley, N.M. Meindl-Beinker.
European Journal of Clinical Investigation (2016), 46 (Suppl. 1), 6-119, 3.28. 

Investigating the role of bone morphogenetic protein and activin membrane-bound inhibitor (BAMBI) in hepatocellular carcinoma (HCC).

T. Dediulia, A. Dropmann, T. Itzel, N.M. Meindl-Beinker, A. Teufel, C. Coulouarn, S. Roessler, I. Fabregat, P.t. Dijke, S. Dooley.
European Journal of Clinical Investigation (2016), 46 (Suppl. 1), 6-119, 3.25. 

Transforming growth factor-beta regulates transendothelial migration during hepatocellular carcinoma progression.

P. Koudelkova, G. Weber, V. Costina, S. Dooley, R. Agarwal, P. Winter, P. Findeisen, W. Mikulits.
European Journal of Clinical Investigation (2016), 46 (Suppl. 1), 6-119, 3.21. 

Cross-tak between TGF-beta-induced Epithelial-Mesenchymal Transition and stemness in hepatocellular carcinoma. 

A. Malfettone, J. Soukupova, J. Fernando, P. Koudelkova, E. Bertran, A. Fabra, M. Grubinger, B. Rani, G. Giannelli, W. Mikulits, Fabregat I.
European Journal of Clinical Investigation (2016), 46 (Suppl. 1), 6-119, 3.18.

Relevance of bmp9-mediated signaling in oval cell function during chronic liver injury. Cross-talk with the hgf/c-met pathway. 

A. Addante, M. García-Álvaro, C. Roncero, L. Almale, N. Deleyto, M. Fernández, I. Fabregat, B. Herrera, A. Sánchez.
European Journal of Clinical Investigation (2016), 46 (Suppl. 1), 6-119, 3.27.

A transforming growth factor kinase I inhibitor, galunisertib (LY215299), modulates stemness-related biomarkers in HCC. 

B. Rani, F. Dituri, A. Malfettone, Y. Cao, L. Lupo, I. Fabregat, G. Giannelli.
European Journal of Clinical Investigation (2016), 46 (Suppl. 1), 6-119, 3.29.

BMP9 effect on liver cells depends on their transformation and differentiation status. 

M. Garcia-Alvaro, A. Addante, L. Amale, M. Fernandez, C. Roncero, I. Fabregat, A. Sánchez, B. Herrera.
European Journal of Clinical Investigation (2016), 46 (Suppl. 1), 6-119, 3.31.

TGF-B2-target to tackle chronic liver diseases using antisense oligonucleotides.

A. Dropmann, H. Korhonen, M. Janicot, S. Dooley, N. Meindl-Beinker. 

Journal of Hepatology (2016) Suppl. 2 Vol. 64, S704 (SAT-385). 

Transforming growth factor-beta triggers transendothelial migration during hepatocellular carcinoma progression.

P. Koudelkova, G. Weber, V. Costina, S. Dooley, R. Agarwal, P. Winter, P. Findeisen, W. Mikulits.
Journal of Hepatology (2016) Suppl. 2 Vol. 64, S581 (FRI-096). 

Hepatocyte-specific Smad7 deletion accelerates den induced mouse hepatocellular carcinoma via activation of STAT3 signaling.

 

T. Feng, J. Dzieran, T. Maass, A. Teufel, S. Marhenke, A. Vogel, S. Dooley, N. Meindl-Beinker.

Journal of Hepatology (2016) Suppl. 2 Vol. 64, S572 (FRI-072).

Tackling fibrosis using TGF-β2 targeted AONs in vivo.

 

A. Dropmann, H. Korhonen, F. Jaschinski, M. Janicot, N. Meindl-Beinker, S. Dooley.
Journal of Hepatology (2015) Suppl. 2 Vol. 62, S263-S864 (PO441).

Delta like ligand 4 drives liver damage through regulating chemokines.

 

Z. Shen, Y. Liu, J. Hu, O. Park, T. Feng, B. Dewidar, C. Xu, C. Yu, H. Li, H.G. Augustin, P. ten Dijke, B. Gao, M.P.A. Ebert, S. Dooley, Y. Li, H. Weng.
Journal of Hepatology (2015) Suppl. 2 Vol. 62, S263-S864 (PO430). 

Multicenter analysis of soluble Axl reveals diagnostic value for very early stage hepatocellular carcinoma.

P. Reichl, M. Fang, P. Starlinger, K. Staufer, R. Nenutil , P. Muller, K. Greplova, D. Valik, S. Dooley, C. Brostjan, T. Gruenberger, J. Shen, K. Man, M. Trauner, J. Yu, C.F. Gao, W. Mikulits.
Journal of Hepatology (2015) Suppl. 2 Vol. 62, S263-S864 (PO346).

Glypican-3 promotes hepatocellular carcinoma progression and metastasis by activation of the ERK signaling pathway.

 

Y. Wu, H. Liu, H. Weng, X. Zhang, P. Li, C. Fan, B. Li, P. Dong, L. Li, S. Dooley, H. Ding.

Journal of Hepatology (2015) Suppl. 2 Vol. 62, S263-S864 (PO322).

Targeting TGF-beta I with the transforming growth factor receptor type I kinase inhibitor, LY2157299, modulates stemness-related biomarkers in hepatocellular carcinoma.
 
B. Rani, F. Dituri, Y. Cao, U. Engström, L. Lupo, S. Dooley, A. Moustakas, G. Giannelli.
Journal of Hepatology (2015) Suppl. 2 Vol. 62, S263-S864 (PO320).

Identification of molecular alterations induced by targeting metabolism in hepatocellular carcinoma. 

Z.C.F. Nwosu, J. Moreno-Cáceres, C. Meyer, S. Dooley.

Journal of Hepatology (2015) Suppl. 2 Vol. 62, S263-S864 (PO319). 

Transendothelial migration depends on transforming growth factor beta in hepatocellular carcinoma progression.

 

P. Koudelkova, G. Weber, S. Dooley, V. Costina, P. Findeisen, W. Mikulits.

Journal of Hepatology (2015) Suppl. 2 Vol. 62, S263-S864 (PO259).

Relevance of BMP9-mediated signlaing in oval cell function during liver injury. Cross-talk with the HGF/Met pathway.

A. Addante, M. Garcia-Alvaro, C. Roncero, L. Almale, N. Deleyto, M. Fernandez, I. Fabregat, B. Herrera, A. Sanchez.
Journal of Hepatology (2015) Suppl. 2 Vol. 62, S469-S470 (PO416).

The Transforming Growth Factor-beta (TGF-beta) governs human liver tumor cell plasticity.

A. Malfettone, J. Fernando, P. Koudelkova, J. Soukupova, E. Bertran, A. Fabra, M. Grubinger, B. Rani, G. Giannelli, W. Mikulits, I. Fabregat.
Journal of Hepatology (2015) Suppl. 2 Vol. 62, S419-S420 (PO297).

Screening for TGF-β signaling regulator expression in human HCC.

T. Dediulia, A. Dropmann, T. Itzel, N. Meindl-Beinker, A. Teufel, S. Cai, P. ten Dijke, S. Dooley.

Z Gastroenterol (2014), 52, 65-137, P.4.41. 

TGF-β2 in chronic liver disease (CLD) and Hepatocellular carcinoma (HCC).

A. Dropmann, A. Piiper, E.A. Alonso, S. Weber, K. Abshagen, M. Wieland, S. Nittka, K. Breitkopf-Heinlein, M. Janicot, F. Jaschinski, H. Korhonen, S. Dooley.

Z Gastroenterol (2014), 52, 65-137, P.1.38. 

Caveolin-1 is required for TGF-β-induced transactivation of the EGF receptor pathway in hepatocytes through the activation of the metalloprotease TACE/ADAM17.

J. Moreno-Càceres, L. Caja, J. Mainez, R. Mayoral, P. Martín-Sanz, R. Moreno-Vicente, M.A. Del Pozo, S. Dooley, G. Egea, I. Fabregat.

Cell Death Dis. 2014 Jul 17;5:e1326. doi: 10.1038/cddis.2014.294.